Prospective validation of five malnutrition screening and assessment instruments among medical inpatients: Secondary analysis of a randomized clinical trial.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
06 2022
Historique:
received: 03 03 2022
revised: 19 04 2022
accepted: 19 04 2022
pubmed: 14 5 2022
medline: 7 6 2022
entrez: 13 5 2022
Statut: ppublish

Résumé

Screening for malnutrition upon hospital admission is the first crucial step for proper nutritional assessment and treatment. While several nutritional screening and assessment instruments exist, there is a lack of head-to-head validation of these instruments. We studied the ability of five different nutrition screening and assessment instruments to predict 1-year mortality and response to nutritional treatment in participants of the EFFORT randomized trial. In this secondary analysis of a Swiss-wide multicenter, randomized clinical trial comparing individualized nutritional support with usual care nutrition in medical inpatients, we prospectively classified patients as low, intermediate, and high nutritional risk based on five nutritional screening and assessment instruments (NRS 2002, SGA, SNAQ, MNA and MUST). Overall mortality at 1-year in the 1866 included patients was 30.4%. There were significant correlations and a significant concordance between all instruments with r-values ranging from 0.23 to 0.55 and kappa values ranging from 0.10 to 0.36. While high nutritional risk was associated with higher mortality in all instruments, SGA and MNA showed the strongest association with adjusted odds ratios of 3.17 (95%CI, 2.18 to 4.61, p < 0.001) and 3.45 (95%CI, 2.28 to 5.22, p < 0.001). When comparing mortality in intervention group patients to control group patients stratified by severity of malnutrition, there was overall no clear trend towards more benefit in patients with more severe malnutrition, with NRS 2002 and SGA showing the most pronounced relationship between the severity of malnutrition and reduction in mortality as a response to nutritional support. Among all five screening and assessment instruments, higher nutritional risk was associated with higher risk for mortality and adverse clinical outcome, but not with more or less treatment response from nutritional support with differences among scores. Adding more specific parameters to these instruments is important when using them to decide for or against nutritional support interventions in an individual patient. ClinicalTrials.gov NCT02517476.

Sections du résumé

BACKGROUND & AIMS
Screening for malnutrition upon hospital admission is the first crucial step for proper nutritional assessment and treatment. While several nutritional screening and assessment instruments exist, there is a lack of head-to-head validation of these instruments. We studied the ability of five different nutrition screening and assessment instruments to predict 1-year mortality and response to nutritional treatment in participants of the EFFORT randomized trial.
METHODS
In this secondary analysis of a Swiss-wide multicenter, randomized clinical trial comparing individualized nutritional support with usual care nutrition in medical inpatients, we prospectively classified patients as low, intermediate, and high nutritional risk based on five nutritional screening and assessment instruments (NRS 2002, SGA, SNAQ, MNA and MUST).
RESULTS
Overall mortality at 1-year in the 1866 included patients was 30.4%. There were significant correlations and a significant concordance between all instruments with r-values ranging from 0.23 to 0.55 and kappa values ranging from 0.10 to 0.36. While high nutritional risk was associated with higher mortality in all instruments, SGA and MNA showed the strongest association with adjusted odds ratios of 3.17 (95%CI, 2.18 to 4.61, p < 0.001) and 3.45 (95%CI, 2.28 to 5.22, p < 0.001). When comparing mortality in intervention group patients to control group patients stratified by severity of malnutrition, there was overall no clear trend towards more benefit in patients with more severe malnutrition, with NRS 2002 and SGA showing the most pronounced relationship between the severity of malnutrition and reduction in mortality as a response to nutritional support.
CONCLUSION
Among all five screening and assessment instruments, higher nutritional risk was associated with higher risk for mortality and adverse clinical outcome, but not with more or less treatment response from nutritional support with differences among scores. Adding more specific parameters to these instruments is important when using them to decide for or against nutritional support interventions in an individual patient.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02517476.

Identifiants

pubmed: 35552050
pii: S0261-5614(22)00144-3
doi: 10.1016/j.clnu.2022.04.025
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02517476']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1307-1315

Informations de copyright

Copyright © 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The study was investigator-initiated and supported by a grant from the Swiss National Science Foundation, Switzerland, to P. Schuetz (SNSF Professorship, PP00P3_150,531) and the Forschungsrat of the Kantonsspital Aarau, Switzerland (1410.000.058 and 1410.000.044). The Institution of P. Schuetz has previously received unrestricted grant money unrelated to this project from Nestle Health Science, Switzerland, and Abbott Nutrition, United States. The institution of Z. Stanga received speaking honoraria and research support from Nestle Health Science, Switzerland, Abbott Nutrition, United States, Fresenius Kabi, Germany and B.Braun, Germany. All other authors report no conflicts of interest.

Auteurs

Lena Stalder (L)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Nina Kaegi-Braun (N)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Carla Gressies (C)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Claudia Gregoriano (C)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Pascal Tribolet (P)

Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland.

Dileep N Lobo (DN)

Gastrointestinal Surgery, Nottingham Digestive Diseases Centre, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, UK; MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, UK.

Filomena Gomes (F)

The New York Academy of Sciences, New York, NY, USA; NOVA Medical School, Lisboa, Portugal.

Claus Hoess (C)

Internal Medicine, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.

Vojtech Pavlicek (V)

Internal Medicine, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.

Stefan Bilz (S)

Internal Medicine and Endocrinology, Kantonsspital St Gallen, St Gallen, Switzerland.

Sarah Sigrist (S)

Internal Medicine and Endocrinology, Kantonsspital St Gallen, St Gallen, Switzerland.

Michael Brändle (M)

Internal Medicine and Endocrinology, Kantonsspital St Gallen, St Gallen, Switzerland.

Christoph Henzen (C)

Internal Medicine, Kantonsspital Luzern, Luzern, Switzerland.

Robert Thomann (R)

Internal Medicine, Bürgerspital Solothurn, Solothurn, Switzerland.

Jonas Rutishauser (J)

Internal Medicine, Kantonsspital Baden, Switzerland.

Drahomir Aujesky (D)

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Nicolas Rodondi (N)

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.

Jacques Donzé (J)

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Zeno Stanga (Z)

Division of Diabetology, Endocrinology, Nutritional Medicine, and Metabolism Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Beat Mueller (B)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland.

Philipp Schuetz (P)

Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland. Electronic address: schuetzph@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH